Dr. Gatti-Mays on Selecting Between FDA-Approved Assays for PD-L1 Expression in Breast Cancer
May 11th 2021Margaret E. Gatti-Mays, MD, MPH, FACP, discusses considerations for selecting between FDA-approved companion diagnostic assays for measuring PD-L1 expression in triple-negative breast cancer.
Read More